본문 바로가기
KERD
논문KCI 등재

Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson’s disease

설원기
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2010.04|BMB Reports|제43권 제4호|pp. 233-244

2

조회

0

다운로드

10

인용

0

참고문헌

키워드

Parkinson’s diseaseKinaseLRRK2GTPaseG2019S
주제분류화학

초록

Parkinson’s disease (PD) is the second most common neurodegenerative disease, and 5-10% of the PD cases are genetically inherited as familial PD (FPD). LRRK2 (leucine-rich repeat kinase 2) was first reported in 2004 as a gene corresponding to PARK8, an autosomal gene whose dominant mutations cause familial PD. LRRK2 contains both active kinase and GTPase domains as well as protein-protein interaction motifs such as LRR (leucine-rich repeat) and WD40. Most pathogenic LRRK2 mutations are located in either the GTPase or kinase domain, implying important roles for the enzymatic activities in PD pathogenic mechanisms. In comparison to other PD causative genes such as parkin and PINK1, LRRK2 exhibits two important features. One is that LRRK2’s mutations (especially the G2019S mutation) were observed in sporadic as well as familial PD patients. Another is that, among the various PDcausing genes, pathological characteristics observed in patients carrying LRRK2 mutations are the most similar to patients with sporadic PD. Because of these two observations, LRRK2 has been intensively investigated for its pathogenic mechanism (s)and as a target gene for PD therapeutics. In this review, the general biochemical and molecular features of LRRK2, the recent results of LRRK2 studies and LRRK2’s therapeutic potential as a PD target gene will be discussed.

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disease, and 5-10% of the PD cases are genetically inherited as familial PD (FPD). LRRK2 (leucine-rich repeat kinase 2) was first reported in 2004 as a gene corresponding to PARK8, an autosomal gene whose dominant mutations cause familial PD. LRRK2 contains both active kinase and GTPase domains as well as protein-protein interaction motifs such as LRR (leucine-rich repeat) and WD40. Most pathogenic LRRK2 mutations are located in either the GTPase or kinase domain, implying important roles for the enzymatic activities in PD pathogenic mechanisms. In comparison to other PD causative genes such as parkin and PINK1, LRRK2 exhibits two important features. One is that LRRK2’s mutations (especially the G2019S mutation) were observed in sporadic as well as familial PD patients. Another is that, among the various PDcausing genes, pathological characteristics observed in patients carrying LRRK2 mutations are the most similar to patients with sporadic PD. Because of these two observations, LRRK2 has been intensively investigated for its pathogenic mechanism (s)and as a target gene for PD therapeutics. In this review, the general biochemical and molecular features of LRRK2, the recent results of LRRK2 studies and LRRK2’s therapeutic potential as a PD target gene will be discussed.

참고문헌 (124)

  1. Olanow, C. W., "Etiology and pathogenesis of Parkinson's disease", Annu. Rev. Neurosci., 22, pp.123~144 (1999)
  2. Moore, D. J., "Molecular pathophysiology of Parkinson's disease", Annu. Rev. Neurosci., 28, pp.57~87 (2005)
  3. Thomas, B., "Parkinson's disease", Hum. Mol. Genet., 16(2), pp.R183~R194 (2007)
  4. Fahn, S., "Levodopa in the treatment of Parkinson's disease", J. Neural. Transm., 71, pp.1~15 (2006)
  5. Halpern, C., "Deep brain stimulation in neurologic disorders", Parkinsonism Relat. Disord., 13, pp.1~16 (2007)
  6. Lewthwaite, A. J., "Genetics of parkinsonism", Curr. Neurol. Neurosci. Rep., 5, pp.397~404 (2005)
  7. Belin, A. C., "Parkinson's disease: a genetic perspective", FEBS J., 275, pp.1377~1383 (2008)
  8. Farrer, M., "Low frequency of alpha-synuclein mutations in familial Parkinson's disease", Ann. Neurol., 43, pp.394~397 (1998)
  9. Ibanez, P., "Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease", Lancet, 364, pp.1169~1171 (2004)
  10. Chartier-Harlin, M. C., "Alpha-synuclein locus duplication as a cause of familial Parkinson's disease", Lancet, 364, pp.1167~1169 (2004)
  11. Farrer, M., "Comparison of kindreds with parkinsonism and alphasynuclein genomic multiplications", Ann. Neurol., 55, pp.174~179 (2004)
  12. Zimprich, A., "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology", Neuron, 44, pp.601~607 (2004)
  13. Paisan-Ruiz, C., "Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease", Neuron, 44, pp.595~600 (2004)
  14. Satake, W., "Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease", Nat. Genet., 41, pp.1303~1307 (2009)
  15. Funayama, M., "A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1", Ann. Neurol., 51, pp.296~301 (2002)
  16. Bosgraaf, L., "Roc, a Ras", GTPase domain in complex proteins, 2003, pp.1643, 5~10
  17. Korr, D., "LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain", Cell Signal, 18, pp.910~920 (2006)
  18. West, A. B., "Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity", Proc. Natl. Acad. Sci. U.S.A., 통권 : 102, pp.16842~16847 (2005)
  19. Smith, W. W., "Kinase activity of mutant LRRK2 mediates neuronal toxicity", Nat. Neurosci., 9, pp.1231~1233 (2006)
  20. Gandhi, P. N., "Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease", J. Neurosci. Res., 87, pp.1283~1295 (2009)
  21. Lee, S. B., "Loss of LRRK2", PARK8 induces degeneration of dopaminergic neurons in Drosophila, 2007, pp.358, 534~539
  22. Sakaguchi-Nakashima, A., "LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins", Curr. Biol., 17, pp.592~598 (2007)
  23. Simon-Sanchez, J., "LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain", Eur. J. Neurosci., 23, pp.659~666 (2006)
  24. Melrose, H., "Anatomical localization of leucine-rich repeat kinase 2 in mouse brain", Neuroscience, 139, pp.791~794 (2006)
  25. Higashi, S., "Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain", J. Neurochem., 100, pp.363~381 (2007)
  26. Han, B. S., "Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra", Neurosci. Lett., 442, pp.190~194 (2008)
  27. Kitada, T., "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism", Nature, 392, pp.605~608 (1998)
  28. Unoki, M., "Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway", Oncogene, 20, pp.4457~4465 (2001)
  29. Hatano, T., "Leucine-rich repeat kinase 2 associates with lipid rafts", Hum. Mol. Genet., 16, pp.678~690 (2007)
  30. Shin, N., "LRRK2 regulates synaptic vesicle endocytosis", Exp. Cell Res., 314, pp.2055~2065 (2008)
  31. Nichols, W. C., "Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease", Lancet, 365, pp.410~412 (2005)
  32. Di Fonzo, A., "A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease", Lancet, 365, pp.412~415 (2005)
  33. Gilks, W. P., "A common LRRK2 mutation in idiopathic Parkinson's disease", Lancet, 365, pp.415~416 (2005)
  34. Tan, E. K., "The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence", Hum. Genet., 120, pp.857~863 (2007)
  35. Ross, O. A., "Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease", Ann. Neurol., 64, pp.88~92 (2008)
  36. Healy, D. G., "Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study", Lancet Neurol., 7, pp.583~590 (2008)
  37. Ozelius, L. J., "LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews", N. Engl. J. Med., 354, pp.424~425 (2006)
  38. Saunders-Pullman, R., "Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia", Neurosci. Lett., 402, pp.92~96 (2006)
  39. Lesage, S., "LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs", N. Engl. J. Med., 354, pp.422~423 (2006)
  40. Hulihan, M. M., "LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study", Lancet Neurol., 7, pp.591~594 (2008)
  41. Lesage, S., "Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans", Hum. Mol. Genet. (2010)
  42. Tan, E. K., "LRRK2 R1628P increases risk of Parkinson's disease: replication evidence", Hum. Genet., 124, pp.287~288 (2008)
  43. Mata, I. F., "Lrrk2 pathogenic substitutions in Parkinson's disease", Neurogenetics, 6, pp.171~177 (2005)
  44. Kay, D. M., "Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation", Mov. Disord., 20, pp.1077~1078 (2005)
  45. Golub, Y., "Genetic factors influencing age at onset in LRRK2-linked Parkinson disease", Parkinsonism Relat. Disord., 15, pp.539~541 (2009)
  46. Haugarvoll, K., "Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease", Neurology, 70, pp.1456~1460 (2008)
  47. Jaleel, M., "LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity", Biochem. J., 405, pp.307~317 (2007)
  48. West, A. B., "Parkinson's diseaseassociated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity", Hum. Mol. Genet., 16, pp.223~232 (2007)
  49. MacLeod, D., "The familial Parkinsonism gene LRRK2 regulates neurite process morphology", Neuron, 52, pp.587~593 (2006)
  50. Melrose, H., "Update on the functional biology of Lrrk2", Future Neurol., 3, pp.669~681 (2008)
  51. GrGreggio, E., "Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions", ASN Neuro., 1, pp.e00002~ (2009)
  52. Bretscher, A., "ERM proteins and merlin: integrators at the cell cortex", Nat. Rev. Mol. Cell. Biol., 3, pp.586~599 (2002)
  53. Parisiadou, L., "Phosphorylation of ezrin", radixin, J. Neurosci., pp.2009, 29[DOI]
  54. Gillardon, F., "Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - a point of convergence in Parkinsonian neurodegeneration?", J. Neurochem., 110, pp.1514~1522 (2009)
  55. Imai, Y., "Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila", EMBO J., 27, pp.2432~2443 (2008)
  56. Tain, L. S., "Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss", Nat. Neurosci., 12, pp.1129~1135 (2009)
  57. Kumar, A., "The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation", PLoS One, 5, pp.e8730~ (2010)
  58. Gloeckner, C. J., "The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3", 6 and MKK4, J. Neurochem., pp.2009, 109[DOI]
  59. Hsu, C. H., "MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2", J. Neurochem., 112, pp.1593~1604 (2010)
  60. Kamikawaji, S., "Identification of the autophosphorylation sites of LRRK2", Biochemistry, 48, pp.10963~10975 (2009)
  61. Nichols, R. J., "Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease", Biochem. J., 424, pp.47~60 (2009)
  62. Narumiya, S., "The small GTPase Rho: cellular functions and signal transduction", J. Biochem., 120, pp.215~228 (1996)
  63. Li, X., "Leucine-rich repeat kinase 2 (LRRK2)", PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C, J. Neurochem., pp.2007, 103[DOI]
  64. Guo, L., "The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity", Exp. Cell Res., 313, pp.3658~3670 (2007)
  65. Lewis, P. A., "The R1441C mutation of LRRK2 disrupts GTP hydrolysis", Biochem. Biophys. Res. Commun., 357, pp.668~671 (2007)
  66. Deng, J., "Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase", Proc. Natl. Acad. Sci. U.S.A., 105, pp.1499~1504 (2008)
  67. Ito, G., "GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease", Biochemistry, 46, pp.1380~1388 (2007)
  68. Liu, M., "Kinetic mechanistic studies of wild-type leucine-rich repeat kinase2: characterization of the kinase and GTPase activities", Biochemistry, 49, pp.2008~2017 (2010)
  69. Greggio, E., "Kinase activity is required for the toxic effects of mutant LRRK2", dardarin, 2006, pp.23, 329~341
  70. Gasper, R., "It takes two to tango: regulation of G proteins by dimerization", Nat. Rev. Mol. Cell Biol., 10, pp.423~429 (2009)
  71. Sen, S., "Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization", J. Biol. Chem., 284, pp.36346~36356 (2009)
  72. Greggio, E., "The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation", J. Biol. Chem., 283, pp.16906~16914 (2008)
  73. Gandhi, P. N., "The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules", J. Neurosci. Res., 86, pp.1711~1720 (2008)
  74. Dachsel, J. C., "Identification of potential protein interactors of Lrrk2", Parkinsonism Relat. Disord., 13, pp.382~385 (2007)
  75. Wang, L., "The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2", J. Neurosci., 28, pp.3384~3391 (2008)
  76. Ko, H. S., "CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity", Proc. Natl. Acad. Sci. U.S.A., 통권 : 106, pp.2897~2902 (2009)
  77. Ding, X., "Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP", PLoS One, 4, pp.e5949~ (2009)
  78. Ohta, E., "I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wildtype molecule", Biochem. Biophys. Res. Commun., 390, pp.710~715 (2009)
  79. Ohta, E., "Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis", Biochem. Biophys. Res. Commun., 391, pp.242~247 (2010)
  80. Ho, C. C., "The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration", J. Neurosci., 29, pp.1011~1016 (2009)
  81. Sancho, R. M., "Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways", Hum. Mol. Genet., 18, pp.3955~3968 (2009)
  82. Smith, W. W., "Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration", Proc. Natl. Acad. Sci. U.S.A., 통권 : 102, pp.18676~18681 (2005)
  83. Venderova, K., "Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease", Hum. Mol. Genet., 18, pp.4390~4404 (2009)
  84. Samann, J., "Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth", J. Biol. Chem., 284, pp.16482~16491 (2009)
  85. Lin, X., "Leucinerich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein", Neuron, 64, pp.807~827 (2009)
  86. Ng, C. H., "Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila", J. Neurosci., 29, pp.11162~11257 (2009)
  87. Plowey, E. D., "Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells", J. Neurochem., 105, pp.1048~1056 (2008)
  88. Liou, A. K., "Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway", Neurobiol. Dis., 32, pp.116~124 (2008)
  89. Heo, H. Y., "LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity", Exp. Cell Res., 316, pp.649~656 (2010)
  90. Alegre-Abarrategui, J., "LRRK2 regulates autophagic activity and localises to specific membrane microdomains in a novel human genomic reporter cellular model", Hum. Mol. Genet., 18, pp.4022~4033 (2009)
  91. Iaccarino, C., "Apoptotic mechanisms in mutant LRRK2-mediated cell death", Hum. Mol. Genet., 16, pp.1319~1326 (2007)
  92. Carballo-Carbajal, I., "Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway", Cell Signal, 22, pp.821~827 (2010)
  93. Li, Y., "Mutant LRRK2 (R1441G) BAC transgenic mice recapi tulate cardinal features of Parkinson's disease", Nat. Neurosci., 12, pp.826~828 (2009)
  94. Tong, Y., "R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice", Proc. Natl. Acad. Sci. U.S.A., 통권 : 106, pp.14622~14627 (2009)
  95. Li, X., "Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S", J. Neurosci., 30, pp.1788~1797 (2010)
  96. Saha, S., "LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans", J. Neurosci., 29, pp.9210~9218 (2009)
  97. Wang, D., "Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons", Mol. Neurodegener., 3, pp.3~ (2008)
  98. Liu, Z., "A Drosophila model for LRRK2-linked parkinsonism", Proc. Natl. Acad. Sci. U.S.A., 통권 : 105, pp.2693~2698 (2008)
  99. White, L. R., "MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease", J. Neurosci. Res., 85, pp.1288~1294 (2007)
  100. Mutez, E., "Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation", Neurobiol. Aging. (2010)
  101. Johansen, K. K., "Metabolomic profiling in LRRK2-related Parkinson's disease", PLoS One, 4, pp.e7551~ (2009)
  102. Church, W. H., "Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation", Brain Res. Bull., 33, pp.419~425 (1994)
  103. Covy, J. P., "Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2", Biochem. Biophys. Res. Commun., 378, pp.473~477 (2009)
  104. Yue, Z., "LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles", FEBS J., 276, pp.6445~6454 (2009)
  105. Webber, P. J., "LRRK2 in Parkinson's disease: function in cells and neurodegeneration", FEBS J., 276, pp.6436~6444 (2009)
  106. Kumari, U., "LRRK2 in Parkinson's disease: genetic and clinical studies from patients", FEBS J., 276, pp.6455~6463 (2009)
  107. Braithwaite, S. P., "LRRK2 in Parkinson's disease: building an understanding of disease etiology", FEBS J., 276, pp.6427~ (2009)
  108. Anand, V. S., "LRRK2 in Parkinson's disease: biochemical functions", FEBS J., 276, pp.6428~6435 (2009)
  109. Polymeropoulos, M. H., "Mutation in the alpha-synuclein gene identified in families with Parkinson's disease", Science, 276, pp.2045~2047 (1997)
  110. Gasser, T., "A susceptibility locus for Parkinson's disease maps to chromosome 2p13", Nat. Genet., 18, pp.262~265 (1998)
  111. Leroy, E., "The ubiquitin pathway in Parkinson's disease", Nature, 395, pp.451~452 (1998)
  112. Valente, E. M., "Hereditary early-onset Parkinson's disease caused by mutations in PINK1", Science, 304, pp.1158~1160 (2004)
  113. Bonifati, V., "Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism", Science, 299, pp.256~259 (2003)
  114. Ramirez, A., "Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase", Nat. Genet., 38, pp.1184~1191 (2006)
  115. Li, Y. J., "Age at onset in two common neurodegenerative diseases is genetically controlled", Am. J. Hum. Genet., 70, pp.985~993 (2002)
  116. Lautier, C., "Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease", Am. J. Hum. Genet., 82, pp.822~833 (2008)
  117. Pankratz, N., "Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations", Am. J. Hum. Genet., 71, pp.124~135 (2002)
  118. Strauss, K. M., "Loss of function mutations in the gene encoding Omi", HtrA2 in Parkinson's disease, 2005, pp.14, 2099~2111
  119. Paisan-Ruiz, C., "Characterization of PLA2G6 as a locus for dystonia-parkinsonism", Ann. Neurol., 65, pp.19~23 (2009)
  120. Shojaee, S., "Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays", Am. J. Hum. Genet., 82, pp.1375~1384 (2008)
  121. Di Fonzo, A., "FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome", Neurology, 72, pp.240~245 (2009)
  122. Healy, D. G., "UCHL-1 is not a Parkinson's disease susceptibility gene", Ann. Neurol., 59, pp.627~633 (2006)
  123. Nichols, W. C., "Variation in GIGYF2 is not associated with Parkinson disease", Neurology, 72, pp.1886~1892 (2009)
  124. Vilarino-Guell, C., "Reported mutations in GIGYF2 are not a common cause of Parkinson's disease", Mov. Disord., 24, pp.619~620 (2009)

관련 논문AI추천

Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson’s disease and beyond배재열, 이병대생화학분자생물학회 · BMB Reports2015 · 제48권 제5호LRRK2 and membrane trafficking: nexus of Parkinson's disease이병대, 장은해, 정가람, 허은미생화학분자생물학회 · BMB Reports2019 · 제52권 제9호The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson’s Disease and Multiple System Atrophy김성연, 박성섭, 전범석, 조진환대한신경과학회 · Journal of Clinical Neurology2009 · 제5권 제1호Presynaptic Dysfunction by Familial Factors in Parkinson Disease고솔미, 김성현, 이원경, 황순도대한배뇨장애요실금학회 · International Neurourology Journal2018 · 제22권 제1호파킨슨병의 원인유전자와 연관된 자가포식현상서혜명, 설원기, 손일홍, 호동환대한신경과학회 · 대한신경과학회지2014 · 제32권 제3호Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson’s disease오요한, Bokwang Kim, Hajung Yoo, Heechang Moon, Huisu Jeong, Jeongmin Lee, Junho K. Hur, Kyungmi Lee, Woo Jeung Song생화학분자생물학회 · BMB Reports2022 · 제55권 제7호

이 간행물의 다른 논문 (11건)

The role of neuroinflammation on the pathogenesis of Parkinson’s disease허수희, 정영철, 복유진, 진병관, 남진한, 고혁완pp. 225-232Inhibitory effects of KHG26377 on glutamate dehydrogenase activity in cultured islets조성우, 최수영, 양승주, 한호규pp. 245-249Enhancement of immunomodulatory activity by liposome-encapsulated natural phosphodiester bond CpG-DNA in a human B cell line이영희, 김영은, 최수영, 박진서, 권상훈, 권형주, 김동범, Jae Won Rheepp. 250-256Influence of the lung mechanical ventilation with injurious parameters on 7-ketocholesterol synthesis in Sus ScrofaPavel Martasek, Oxana V. Klimenko, Vaclav Vobrubapp. 257-262Phosphorylation on the PPP2R5D B regulatory subunit modulates the biochemical properties of protein phosphatase 2AUn Young Yu, 안정혁pp. 263-267
원문 보기